AU2008322676B9 - Pyridazinone derivatives as PARP inhibitors - Google Patents

Pyridazinone derivatives as PARP inhibitors Download PDF

Info

Publication number
AU2008322676B9
AU2008322676B9 AU2008322676A AU2008322676A AU2008322676B9 AU 2008322676 B9 AU2008322676 B9 AU 2008322676B9 AU 2008322676 A AU2008322676 A AU 2008322676A AU 2008322676 A AU2008322676 A AU 2008322676A AU 2008322676 B9 AU2008322676 B9 AU 2008322676B9
Authority
AU
Australia
Prior art keywords
oxo
carbonyl
oxopiperazin
dihydropyridazin
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008322676A
Other languages
English (en)
Other versions
AU2008322676B2 (en
AU2008322676A1 (en
Inventor
Danila Branca
Gabriella Dessole
Federica Ferrigno
Philip Jones
Olaf Kinzel
Samuele Lillini
Ester Muraglia
Giovanna Pescatore
Carsten Schultz-Fademrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Original Assignee
MSD Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0722401A external-priority patent/GB0722401D0/en
Priority claimed from GB0816707A external-priority patent/GB0816707D0/en
Application filed by MSD Italia SRL filed Critical MSD Italia SRL
Publication of AU2008322676A1 publication Critical patent/AU2008322676A1/en
Publication of AU2008322676B2 publication Critical patent/AU2008322676B2/en
Application granted granted Critical
Publication of AU2008322676B9 publication Critical patent/AU2008322676B9/en
Assigned to MSD ITALIA S.R.L. reassignment MSD ITALIA S.R.L. Request for Assignment Assignors: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2008322676A 2007-11-15 2008-11-14 Pyridazinone derivatives as PARP inhibitors Active AU2008322676B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0722401.7 2007-11-15
GB0722401A GB0722401D0 (en) 2007-11-15 2007-11-15 Therapeutic compounds
GB0816707.4 2008-09-12
GB0816707A GB0816707D0 (en) 2008-09-12 2008-09-12 Therapeutic compounds
PCT/GB2008/051063 WO2009063244A1 (en) 2007-11-15 2008-11-14 Pyridazinone derivatives as parp inhibitors

Publications (3)

Publication Number Publication Date
AU2008322676A1 AU2008322676A1 (en) 2009-05-22
AU2008322676B2 AU2008322676B2 (en) 2013-12-05
AU2008322676B9 true AU2008322676B9 (en) 2014-03-27

Family

ID=40427149

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008322676A Active AU2008322676B9 (en) 2007-11-15 2008-11-14 Pyridazinone derivatives as PARP inhibitors

Country Status (14)

Country Link
US (1) US8268827B2 (enExample)
EP (1) EP2220073B1 (enExample)
JP (1) JP5758630B2 (enExample)
KR (1) KR101641596B1 (enExample)
CN (1) CN101855221B (enExample)
AU (1) AU2008322676B9 (enExample)
CA (1) CA2704714C (enExample)
ES (1) ES2524787T3 (enExample)
IL (1) IL205142A (enExample)
MX (1) MX2010005070A (enExample)
NZ (1) NZ585395A (enExample)
RU (1) RU2490265C2 (enExample)
WO (1) WO2009063244A1 (enExample)
ZA (1) ZA201002466B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369186B (zh) * 2009-04-02 2014-07-09 默克专利有限公司 作为自分泌运动因子抑制剂的哌啶和哌嗪衍生物
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CA2829123C (en) * 2011-03-14 2016-04-12 Eternity Bioscience Inc. Quinazolinediones and their use
TWI577693B (zh) 2011-05-31 2017-04-11 江蘇康緣藥業股份有限公司 聚（ａｄｐ-核糖）聚合酶之三環抑制劑
MX2014008071A (es) 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
MX353578B (es) 2011-12-31 2018-01-19 Beigene Ltd Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
EP2804602B1 (en) 2012-01-20 2024-12-04 Del Mar Pharmaceuticals Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
HUE030613T2 (en) 2012-12-31 2017-05-29 Cadila Healthcare Ltd Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
JP6549735B2 (ja) * 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
JP6532599B2 (ja) * 2015-09-02 2019-06-19 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
EP3356330B1 (en) 2015-10-01 2019-11-20 Bristol-Myers Squibb Company Biaryl kinase inhibitors
KR102030016B1 (ko) 2016-09-05 2019-10-08 충남대학교산학협력단 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
CN108383837B (zh) * 2018-02-09 2020-08-11 福建医科大学 一种氨基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
FI3788040T3 (fi) 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
KR102017115B1 (ko) 2018-05-15 2019-09-02 충남대학교산학협력단 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN110818908B (zh) * 2019-08-29 2021-12-17 杭州市富阳区浙工大银湖创新创业研究院 一种用于检测氧化气体的金属有机骨架材料的制备方法
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
WO2021087025A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
US12459899B2 (en) 2019-10-30 2025-11-04 DIGMBIO, Inc. Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient
US20240190844A1 (en) * 2019-10-30 2024-06-13 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
AU2020444056A1 (en) 2020-04-21 2022-11-17 Idience Co., Ltd. Crystalline forms of phthalazinone compound
JP7626783B2 (ja) 2020-04-21 2025-02-07 アイディーエンス カンパニー リミテッド フタラジノン誘導体及びその中間体を調製するプロセス
WO2021224186A1 (en) * 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
CN117425648A (zh) * 2021-03-12 2024-01-19 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CA3212583A1 (en) 2021-03-27 2022-10-06 Daniel Gooding Compositions having improved bioavailability of therapeutics
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
JP2024528021A (ja) * 2021-07-29 2024-07-26 上海齊魯制藥研究中心有限公司 新規なｐａｒｐ７阻害剤及びその使用
WO2023011629A1 (zh) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
AU2022375782B2 (en) * 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN116375688B (zh) * 2021-12-23 2025-04-11 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
EP4493151A2 (en) * 2022-03-14 2025-01-22 TRX Biosciences Limited Compositions having improved bioavailability of therapeutics and uses thereof
JP7763538B2 (ja) * 2022-04-01 2025-11-04 諾沃斯達薬業（上海）有限公司 Ｐａｒｐ７阻害剤及びその使用
JP2025534359A (ja) * 2022-09-30 2025-10-15 アズカラ セラピューティクス インク ピリダジン－３（２ｈ）－オンおよびピリジン－２（１ｈ）－オンのＰＡＲＰ阻害化合物
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025087383A1 (zh) * 2023-10-26 2025-05-01 深圳众格生物科技有限公司 作为parp7抑制剂的化合物
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138351A2 (en) * 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CA2205757C (en) * 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
WO2002090334A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
CN100469769C (zh) * 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
US20050228007A1 (en) 2004-02-26 2005-10-13 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
JP4627315B2 (ja) 2004-03-23 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2005100323A1 (en) * 2004-04-15 2005-10-27 F. Hoffmann-La Roche Ag Process for preparing pyridazinone compounds
JP2008510783A (ja) 2004-08-26 2008-04-10 クドス ファーマシューティカルズ リミテッド ４−ヘテロアリールメチル置換フタラジノン誘導体
DK1919878T3 (da) 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
ES2548353T3 (es) * 2006-12-28 2015-10-15 Abbvie Inc. Inhibidores de poli(ADP-ribosa)polimerasa
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138351A2 (en) * 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)

Also Published As

Publication number Publication date
CN101855221B (zh) 2013-10-30
US8268827B2 (en) 2012-09-18
WO2009063244A1 (en) 2009-05-22
KR20100087220A (ko) 2010-08-03
BRPI0820236A2 (pt) 2015-06-16
CA2704714C (en) 2018-12-04
RU2490265C2 (ru) 2013-08-20
CA2704714A1 (en) 2009-05-22
AU2008322676B2 (en) 2013-12-05
CN101855221A (zh) 2010-10-06
EP2220073A1 (en) 2010-08-25
ZA201002466B (en) 2010-12-29
JP2011503166A (ja) 2011-01-27
JP5758630B2 (ja) 2015-08-05
NZ585395A (en) 2012-03-30
US20100261709A1 (en) 2010-10-14
IL205142A (en) 2014-09-30
EP2220073B1 (en) 2014-09-03
AU2008322676A1 (en) 2009-05-22
KR101641596B1 (ko) 2016-07-21
IL205142A0 (en) 2010-11-30
MX2010005070A (es) 2010-05-24
ES2524787T3 (es) 2014-12-12
RU2010123874A (ru) 2011-12-20

Similar Documents

Publication Publication Date Title
AU2008322676B9 (en) Pyridazinone derivatives as PARP inhibitors
AU2008204380B2 (en) Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
EP2029551B1 (en) Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
US8436185B2 (en) Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
US8354413B2 (en) Quinolin-4-one and 4-oxodihydrocinnoline derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
AU2009224004A1 (en) Tricyclic derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
NZ578256A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2007283212A1 (en) 4-oxo-4,5-dihydropyrrolo[1,2-A] quinoxaline derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)
BRPI0820236B1 (pt) Compostos derivados de piridazinona, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos
HK40006670A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1131137B (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
HK1154386B (en) Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MSD ITALIA S.R.L.

Free format text: FORMER OWNER WAS: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.